

D John Betteridge BSc, MB BS, PhD, MD, FRCP, FAHA



Professor of Endocrinology and Metabolism, Department of Medicine, University College London Medical School, London, UK

. Professor Betteridge is a past Chairman of the British Hyperlipidaemia Association (now HEART UK) and past President of the Council on Lipids in Clinical Medicine at The Royal Society of Medicine. He is a committee member of the European Chapter of the International Atherosclerosis Society. He is a Fellow of the American Heart Association and a member of numerous international bodies, including the European and American Diabetes Associations and the European Atherosclerosis Society. He is co-chair of the executive committee of CARDS, a major primary CVD prevention trial with atorvastatin in type 2 diabetes. He is the UK Principal Investigator and member of the International Steering Committee for PROactive a major secondary prevention trial with pioglitazone in type 2 diabetes. He is a member of the Clinical Studies Advisory Group of the UK Diabetes Research Network and was a member of the Medical Research Council Steering Committee for the UKPDS. He is a member of the Project Grants Committee of the British Heart Foundation.

Professor Betteridge's main clinical interests are in the care of patients with diabetes mellitus and patients with lipid disorders. His main research interests relate to the pathogenesis of atherosclerosis, and in particular the role of lipoprotein metabolism. He has authored over 300 publications in peer-reviewed journals. His books include Lipoproteins in Health and Disease (Edward Arnold, 1999), Diabetes: Current Perspectives (Martin Dunitz, 2000), Lipids and Vascular Disease (Martin Dunitz, 2000), Case Studies in Diabetes (Martin Dunitz, 2003), Lipids and Coronary Heart Disease (Arnold, 2003) and Case Studies in Lipid Management (Informa Healthcare) 2006